Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors
Active, not recruiting · NCT03610971 · Registry updated 2026-04-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors | Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Myeloproliferative Disorders, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, bone marrow disorder, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Active, not recruiting | Phase 2 | 2026-04-02 | NCT03610971 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| H. Jean Khoury Cure CML Consortium | 3 |
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
| Incyte Corporation | 153 |
8 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| David H. Koch Center for Cancer Care at Memorial Sloan Kettering | New York | United States | 2 |
| Duke University Hospital | Durham | United States | 54 |
| Emory -Winship Cancer Institute | Atlanta | United States | 1 |
| Froedtert Hospital & the Medical College of Wisconsin | Milwaukee | United States | 31 |
| H. Lee Moffitt Cancer Center and Research Institute | Tampa | United States | 32 |
| Memorial Sloan Kettering - Bergen | Montvale | United States | 5 |
| Oregon Health & Science University | Portland | United States | 261 |
| Roswell Park Comprehensive Cancer Center | Buffalo | United States | 63 |